2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
    Neuronal Signaling
  4. iGluR
  5. AMPA Receptor Isoform

AMPA Receptor

 

AMPA Receptor Related Products (80):

Cat. No. Product Name Effect Purity
  • HY-110234
    Topiramate D12
    		Antagonist 99.90%
    Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
  • HY-12499
    (S)-Willardiine
    		Agonist 99.27%
    (S)-Willardiine is a potent agonist of AMPA/kainate receptors with EC50 of 44.
  • HY-15069A
    Fanapanel hydrate
    		Antagonist 99.76%
    Fanapanel hydrate (ZK200775 hydrate) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.
  • HY-16713
    (S)-(-)-5-Fluorowillardiine
    		Agonist
    (S)-(-)-5-Fluorowillardiine is a potent and specific AMPAR agonist.
  • HY-10935
    LY450108
    		Activator 99.51%
    LY450108 is a potent AMPA receptor potentiator. LY450108 has the potential for depression and Parkinson's disease research.
  • HY-12503
    CFM-2
    		Antagonist 98.93%
    CFM-2 is a potent and selective non-competitive AMPAR antagonist. CFM-2 possesses anticonvulsant activity in various models of seizures.
  • HY-103235
    NPEC-caged-(S)-AMPA
    		Activator
    NPEC- caged-(S)-AMPA, a caged neurotransmitter analog, is a NPEC photoprotecting group caged the (S)-AMPA (HY-100815A) to make caged ligands specific for glutamate receptor sub-types. NPEC- caged-(S)-AMPA selectively activates AMPA receptor.
  • HY-124160
    JNJ-56022486
    		Modulator
    JNJ-56022486 is an orally active and potent negative AMPA receptor modulator (Ki=19 nM) selective for?TARP-γ8. JNJ-56022486 is also a TARP-γ8 receptor antagonist, with blood?brain?barrier (BBB) permeability. JNJ-56022486 can be used for research of Epilepsy.
  • HY-103234
    GYKI 52466
    		Antagonist
    GYKI 52466 is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 can be used in Parkinson's disease research.
  • HY-10933S
    CX516-d10
    		Modulator
    CX516-d10 is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI)[1].
  • HY-P3355
    p-fin4
    p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators.
  • HY-19433A
    (S)-ATPO
    (S)-ATPO is the (S)-enantiomer of ATPO, which is a competitive antagonist at GluR1-4 (AMPA-preferring) receptors.
  • HY-161665
    BDZ-P7
    		Inhibitor
    BDZ-P7 inhibits AMPA receptor GluA2, GluA1/2, GluA2/3, and GluA1 subunit with IC50s of 3.03 μM, 3.14 μM, 3.19 μM, 3.2 μM. BDZ-P7 has neuroprotective effect and reinstates locomotor abilities in a mouse model of Parkinson’s disease.
  • HY-100781
    D-AP4
    		Antagonist
    D-AP4 (D-APB; D-2-Amino-4-phosphonobutyric acid), a phosphono analogue of glutamate, is an NMDA broad spectrum excitatory amino acid receptor antagonist. D-AP4 also is an agonist for a quisqualate-sensitized AP6 site in hippocampus. D-AP4 inhibits AMPA receptor-stimulated 57Co2+ influx in cultured cerebellar granule cells (IC50 ≥ 100 μM).
  • HY-14608S
    L-Glutamic acid-13C
    		Agonist
    L-Glutamic acid-13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
  • HY-14608S1
    L-Glutamic acid-1-13C
    		Agonist ≥99.0%
    L-Glutamic acid-1-13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
  • HY-14608S6
    L-Glutamic acid-5-13C
    		Agonist
    L-Glutamic acid-5-13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
  • HY-P3354
    p3Ysh-3
    p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators.
  • HY-125931
    Unifiram
    		Activator 99.78%
    Unifiram (DM232) is acts as a potent cognition enhancer through the activation of the AMPA-mediated neurotransmission system. Unifiram (DM232) has the potential for amnesia prevention and neurodegenerative disorder research.
  • HY-14608S9
    L-Glutamic acid-15N,d5
    		Agonist
    L-Glutamic acid-15N,d5 is the deuterium and 15N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.